Monday, February 10, 2025

AlidaBio Launches EpiPlex to Advance Epitranscriptomic Research

Alida Biosciences, an innovator in epigenomic research tools, announced the full commercial launch of its EpiPlex platform, the first to concurrently detect and quantify multiple RNA modifications by short-read sequencing in addition to providing gene expression data. The platform, which pairs the EpiPlex RNA Reagent Kit and the EpiScout Analysis Suite, provides a comprehensive, single-workflow solution to advance research into the role of RNA modifications in disease, aging and development.

Standard RNA sequencing does not directly detect naturally occurring chemical modifications of RNA, collectively known as the epitranscriptome. Traditional methods for epitranscriptome analysis detect a single type of modification per assay, are labor – and time-intensive, and require specialized expertise and high RNA input, which has limited their use in generating quality data. The EpiPlex platform is designed to allow researchers of all skill levels to accurately and simultaneously detect multiple RNA modifications (N6-methyladenosine and inosine initially, with extendability to others), offering broader insights into the complex relationships between the modifications and dynamic regulatory mechanisms in cancer, neurological and cardiometabolic disease, cell differentiation, viral infection and other phenotypes relevant to human health.

“As a researcher, we’ve often faced challenges with affordable, scalable and user-friendly tools for detecting RNA modifications. The EpiPlex kit has truly exceeded our expectations, enabling the simultaneous detection of two RNA modifications with remarkable ease,” said Roshan Vaid, Ph.D., of the University of Gothenburg in Sweden. “Coupled with the EpiScout platform for bioinformatic analysis, the entire workflow – from data visualization to downstream analysis – became incredibly quick and efficient. This has been a transformative tool for advancing our epitranscriptomic research.”

Also Read: Biofidelity & CellCarta Partner for Aspyre Lung Global Trials

“I am very excited by the ability to simultaneously map multiple epitranscriptomic modifications in a single assay,” said Prof. Richard Gregory, Ph.D., of Harvard University. “We have been impressed by the high quality and reproducibility of the data generated from the samples we have tested.”

“This new technology for epitranscriptome analysis has given us completely new insights into the mechanisms of genome integrity in eukaryotes,” said Prof. Akira Sassa, Ph.D., of Chiba University in Japan. “We are very impressed with the method, which allows highly sensitive and quantitative assessment of multiple RNA modifications.”

“The EpiPlex platform is the first commercial solution to read the epitranscriptome that includes both a sensitive, robust assay and a user-friendly bioinformatics package, making epitranscriptomics broadly accessible,” said Gudrun Stengel, Ph.D., CEO of AlidaBio. “With this highly efficient, cutting-edge tool that offers unprecedented detection of RNA modifications, our goal is to empower researchers across disciplines as they work to discover new biomarkers and therapeutic targets.”

SOURCE: Businesswire

Subscribe Now

    Hot Topics